United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - etidronate disodium (unii: m16pxg993g) (etidronic acid - unii:m2f465roxu) - etidronate disodium 200 mg - etidronate disodium tablets, usp are indicated for the treatment of symptomatic paget’s disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. etidronate disodium tablets are not approved for the treatment of osteoporosis. etidronate disodium tablets are indicated for the treatment of symptomatic paget’s disease of bone. etidronate disodium therapy usually arrests or significantly impedes the disease process as evidenced by: in addition, reductions in pagetically elevated cardiac output and skin temperature have been observed in some patients. in many patients, the disease process will be suppressed for a period of at least one year following cessation of therapy. the upper limit of this period has not been determined. the effects of the etidronate disodium treatment in patients with asymptomatic paget’s disease have not been studied. however, etidronate disodium treatment of such patients may be warranted if extensive invo

United States - English - NLM (National Library of Medicine)

areva pharmaceuticals inc. - pamidronate disodium (unii: 8742t8zqza) (pamidronic acid - unii:oyy3447omc) - pamidronate disodium 3 mg in 1 ml - pamidronate disodium for injection usp, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium for injection usp. vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 l/day throughout treatment. mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. diuretic therapy should not be employed prior to correction of hypovolemia. the safety and efficacy of pamidronate disodium for injection usp in the treatment of hypercalcemia associated with hyperparat

United States - English - NLM (National Library of Medicine)

mylan institutional llc - pamidronate disodium (unii: 8742t8zqza) (pamidronic acid - unii:oyy3447omc) - pamidronate disodium 3 mg in 1 ml - pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 l/day throughout treatment. mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. diuretic therapy should not be employed prior to correction of hypovolemia. the safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions h

United States - English - NLM (National Library of Medicine)

hospira, inc. - pamidronate disodium (unii: 8742t8zqza) (pamidronic acid - unii:oyy3447omc) - pamidronate disodium 6 mg in 1 ml - hypercalcemia of malignancy   pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 l/day throughout treatment. mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. diuretic therapy should not be employed prior to correction of hypovolemia. the safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. paget’s disease   pamidronate disodium is indicated for the treatment of patients with moderate to severe paget’s disease of bone. the effectiveness of pamidronate disodium was demonstrated primarily in patients with serum alkaline phosphatase ≥ 3 times the upper limit of normal. pamidronate disodium therapy in patients with paget’s disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by ≥ 50% in at least 50% of patients, and by ≥ 30% in at least 80% of patients. pamidronate disodium therapy has also been effective in reducing these biochemical markers in patients with paget’s disease who failed to respond, or no longer responded to other treatments. osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. the pamidronate disodium treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated (see clinical pharmacology, osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma, clinical trials section). pamidronate disodium is contraindicated in patients with clinically significant hypersensitivity to pamidronate disodium or other bisphosphonates.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - pamidronate disodium (unii: 8742t8zqza) (pamidronic acid - unii:oyy3447omc) - pamidronate disodium 3 mg in 1 ml - pamidronate disodium injection, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases.  patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium.  vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 l/day throughout treatment.  mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics).  patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided.  diuretic therapy should not be employed prior to correction of hypovolemia.  the safety and efficacy of pamidronate disodium injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-

United States - English - NLM (National Library of Medicine)

teva parenteral medicines, inc. - pamidronate disodium (unii: 8742t8zqza) (pamidronic acid - unii:oyy3447omc) - pamidronate disodium 3 mg in 1 ml - pamidronate disodium injection is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. pamidronate disodium injection is indicated for the treatment of patients with moderate to severe paget’s disease of bone. pamidronate disodium injection is indicated in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma [see clinical studies (14.3)] . the safety and efficacy of pamidronate disodium injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. pamidronate disodium is contraindicated in patients with hypersensitivity to pamidronate disodium, other bisphosphonates, or mannitol. reactions to pamidronate disodium injection and to mannitol have included anaphylaxis. pregnancy category d [see warnings and precautions (5.2)] risk summary there are no ad

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - pemetrexed disodium heptahydrate, quantity: 151.7 mg - injection, powder for - excipient ingredients: hydrochloric acid; mannitol; water for injections; sodium hydroxide - malignant pleural mesothelioma. alimta, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma. non-small cell lung cancer. alimta in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

medac uk - disodium folinate - solution for injection - 50mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

medac uk - disodium folinate - solution for injection - 50mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - disodium edetate - eye drops - 3.7mg/1gram